{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"44.1","value":"8.1"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"33.7","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study.","dispersionType":"Full Range","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population with improvement in ECOG performance status during the study","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.","title":"Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status","type":"SECONDARY","unitOfMeasure":"weeks"}